Literature DB >> 20432045

Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.

Terhi Launiainen1, Ilpo Rasanen, Erkki Vuori, Ilkka Ojanperä.   

Abstract

Venlafaxine (VEN) is an antidepressant found to possess a higher fatal toxicity index (FTI, i.e., deaths in proportion to consumption) than other newer antidepressants and selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to elucidate using post-mortem cases whether the apparent high toxicity of VEN is associated with adverse drug interactions, pharmacogenetic factors and/or the manner of death. Within a 2-year period, a comprehensive post-mortem database and death certificates were searched for cases with laboratory findings of VEN, findings of other drugs, associated background information and the cause and manner of death. In 123 cases, the concentrations of VEN and its two metabolites, O-desmethylvenlafaxine (O-VEN) and N-desmethylvenlafaxine (N-VEN), and the CYP2D6 genotype were determined in post-mortem blood. The median concentrations of VEN, O-VEN and N-VEN were 560, 420 and 49 µg/l, respectively. A prominent feature of the VEN-positive cases was the high abundance of interacting drugs (46%), being more common with higher VEN concentrations. Compared to other common antidepressants, VEN-positive cases showed the highest suicide frequency, but also the proportion of suicidal VEN poisonings of all suicides was substantially higher than that of mirtazapine or SSRIs. Relative CYP2D6 activity did not predispose to high VEN concentrations, and the frequency of the extreme phenotypes followed the general population. In conclusion, the high suicide potential of VEN in combination with the high prevalence of drugs causing adverse interactions could be the reason for the observed high FTI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432045     DOI: 10.1007/s00414-010-0461-5

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  53 in total

1.  Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.

Authors:  Nicholas A Buckley; Peter R McManus
Journal:  BMJ       Date:  2002-12-07

2.  Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000.

Authors:  Survjit Cheeta; Fabrizio Schifano; Adenekan Oyefeso; Lucy Webb; A Hamid Ghodse
Journal:  Br J Psychiatry       Date:  2004-01       Impact factor: 9.319

Review 3.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.

Authors:  J Kirchheiner; K Nickchen; M Bauer; M-L Wong; J Licinio; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

4.  Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

Authors:  S Weinmann; T Becker; M Koesters
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

Review 5.  SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Authors:  Stephen M Stahl; Meghan M Grady; Chantal Moret; Mike Briley
Journal:  CNS Spectr       Date:  2005-09       Impact factor: 3.790

6.  Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.

Authors:  Daniel Mines; Deanna Hill; Holly Yu; Laura Novelli
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-06       Impact factor: 2.890

7.  O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.

Authors:  S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt
Journal:  Neuropsychopharmacology       Date:  1999-05       Impact factor: 7.853

8.  Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.

Authors:  I M Whyte; A H Dawson; N A Buckley
Journal:  QJM       Date:  2003-05

9.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

10.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

View more
  4 in total

Review 1.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

2.  Deaths involving contraindicated and inappropriate combinations of serotonergic drugs.

Authors:  Jennifer L Pilgrim; Dimitri Gerostamoulos; Olaf H Drummer
Journal:  Int J Legal Med       Date:  2010-12-01       Impact factor: 2.686

3.  Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database.

Authors:  Ilkka Ojanperä; Pirkko Kriikku; Erkki Vuori
Journal:  Int J Legal Med       Date:  2016-03-17       Impact factor: 2.686

4.  ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram.

Authors:  L Karlsson; H Green; A L Zackrisson; F Bengtsson; I Jakobsen Falk; B Carlsson; J Ahlner; F C Kugelberg
Journal:  Int J Legal Med       Date:  2013-03-21       Impact factor: 2.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.